Clinuvel Pharmaceuticals (FRA:UR9) Capex-to-Operating-Income : 0.40 (As of Dec. 2023)

Clinuvel Pharmaceuticals Capex-to-Operating-Income Chart

Clinuvel Pharmaceuticals Annual Data
	Trend	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
Capex-to-Operating-Income		Get a 7-Day Free Trial					0.02	0.08	0.03	0.01	0.02

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial															0.01	0.02	0.03	0.02	0.40

Competitive Comparison of Clinuvel Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Capex-to-Operating-Income falls into.

Clinuvel Pharmaceuticals Capex-to-Operating-Income Calculation

Clinuvel Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Clinuvel Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals  (FRA:UR9) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Clinuvel Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (FRA:UR9) Business Description